By otakuyassine3@gmail.com 
10x Genomics (NASDAQ:TXG – Get Free Report)‘s stock had its “sell (e+)” rating reiterated by equities researchers at Weiss Ratings in a research note issued to investors on Saturday,Weiss Ratings reports.
TXG has been the subject of several other research reports. UBS Group dropped their target price on shares of 10x Genomics from $20.00 to $14.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Citigroup dropped their target price on shares of 10x Genomics from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, March 4th. Canaccord Genuity Group dropped their target price on shares of 10x Genomics from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Stifel Nicolaus dropped their target price on shares of 10x Genomics from $21.00 to $18.00 and set a “buy” rating for the company in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. dropped their target price on shares of 10x Genomics from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $20.21.
Read Our Latest Stock Report on TXG
10x Genomics Price Performance
Shares of TXG stock opened at $10.39 on Friday. 10x Genomics has a 12 month low of $9.27 and a 12 month high of $38.49. The firm has a market capitalization of $1.27 billion, a P/E ratio of -6.84 and a beta of 1.93. The company’s fifty day moving average price is $12.68 and its two-hundred day moving average price is $15.47.
10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative return on equity of 25.40% and a negative net margin of 29.90%. On average, sell-side analysts anticipate that 10x Genomics will post -1.43 EPS for the current year.
Insider Transactions at 10x Genomics
In other 10x Genomics news, Director Alan Mateo bought 40,000 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The stock was acquired at an average cost of $11.14 per share, with a total value of $445,600.00. Following the completion of the purchase, the director now directly owns 61,691 shares in the company, valued at approximately $687,237.74. This trade represents a 184.41 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, CEO Serge Saxonov sold 5,092 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $56,368.44. Following the sale, the chief executive officer now directly owns 879,482 shares of the company’s stock, valued at approximately $9,735,865.74. This represents a 0.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 10.03% of the company’s stock.
Institutional Trading of 10x Genomics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Signaturefd LLC raised its holdings in shares of 10x Genomics by 424.6% during the fourth quarter. Signaturefd LLC now owns 1,794 shares of the company’s stock valued at $26,000 after acquiring an additional 1,452 shares during the period. GF Fund Management CO. LTD. acquired a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $32,000. Blue Trust Inc. raised its holdings in shares of 10x Genomics by 73.1% during the fourth quarter. Blue Trust Inc. now owns 3,075 shares of the company’s stock valued at $44,000 after acquiring an additional 1,299 shares during the period. Sound Income Strategies LLC raised its holdings in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company’s stock valued at $48,000 after acquiring an additional 1,330 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of 10x Genomics during the fourth quarter valued at approximately $52,000. 84.68% of the stock is owned by institutional investors and hedge funds.
About 10x Genomics
10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.
Read More
Receive News & Ratings for 10x Genomics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for 10x Genomics and related companies with MarketBeat.com’s FREE daily email newsletter.